苯磺酸氨氯地平治疗高血压临床观察(1)
 |
| 第1页 |
参见附件(1881KB，2页)。
[摘要] 目的：探讨苯磺酸氨氯地平治疗高血压的临床疗效及安全性。方法：将社区门诊确诊的100例高血压患者随机分为对照组与观察组，每组50例，对照组给予硝苯地平治疗；观察组给予苯磺酸氨氯地平治疗，8周为1个疗程，两组均治疗1个疗程后，观察临床疗效，比较两组治疗前后的心率和血压变化情况及不良反应发生率。结果：观察组治疗后的收缩压和舒张压均明显低于对照组(P<0.05)，两组治疗前后心率变化无统计学意义(P>0.05)；观察组的显效率为74.0%，总有效率为96.0%，均高于对照组的62.0%和86.0%(P<0.05)；两组不良反应比较无统计学意义(P>0.05)。结论：苯磺酸氨氯地平是一种安全有效的治疗高血压药物。
[关键词] 苯磺酸氨氯地平 硝苯地平 高血压 临床观察
[中图分类号] R544.1[文献标识码]A [文章编号]1673-7210(2011)02(c)-049-02
Clinical observation on treatment of hypertension with amlodipine besylate
YU Lianhong
(Hospital of Wuhan Textile University, Wuhan430073, China)
[Abstract] Objective: To investigate the efficacy and safety about the treatment of hypertension with amlodipine besylate. Methods: 100 patients with hypertension were randomly divided into control group and observation group, n=50, the control group was given nifedipine; the observation group received the treatment with amlodipine besylate. One course lasted 8 weeks. After one course, the two groups were compared on the heart rate， blood pressure and adverse reaction rate. Results:After treatment, the systolic and diastolic blood pressure were significantly lower than the control group, the heart rate changes before and after treatment in both groups was not significant; obvious effective rate and effective rate of the observation group was 74.0% and 96.0%, which was higher than 62.0% and 86.0% of the control group; the two groups showed no statistically significant in adverse effects. Conclusion: Amlodipine besylate is a safe and effective treatment for hypertension.
[Key words] Amlodipine besylate; Nifedipine; Hypertension; Clinical observation
高血压病是一种多基因遗传和环境危害因素互相作用而造成的全身性疾病，近些年来发病率不断上升[1]。大量临床试验的证据表明，积极降压治疗可显著降低高血压病患者脑卒中及心血管事件的发生率及死亡率[2]。治疗高血压的药物众多，钙离子拮抗剂是WHO推荐的治疗高血压的一线药物。苯磺酸氨氯地平是新一代钙离子拮抗剂，起效快，不良反应少，作用持续时间长，越来越受到临床医生及患者的青睐。笔者在社区门诊应用苯磺酸氨氯地平治疗高血压患者50例，取得了良好的效果，现报道如下。
1资料与方法
1.1 一般资料
选择2009年9月~2010年10月在社区门诊就医的高血压患者100例作为研究对象，所有患者均符合WHO高血压的诊断标准。男66例，女34例；年龄38~76岁，平均(52.3±7.2)岁；病程1~10年，平均(5.8±2.6)年，实验室检查排除继发性高血压、肺心病、糖尿病、冠心病、急性心力衰竭及肝肾功能障碍等。随机分为对照组和观察组，对照组50例，男32例，女18例，年龄(51.5±7.0)岁，病程(5.6±2 ......
您现在查看是摘要介绍页，详见PDF附件(1881KB，2页)。